<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662894</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0815</org_study_id>
    <nct_id>NCT02662894</nct_id>
  </id_info>
  <brief_title>Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.</brief_title>
  <official_title>Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin
      versus their isolated components in treatment of hypertension and dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Open-label,randomized, multicenter;

        -  Maximal experiment duration: 8 weeks;

        -  04 visits;

        -  Safety and efficacy evaluation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of systemic blood pressure measured between the first visit and last visit.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who reach the goal of LDL-C according to intermediate risk rating ( LDLc &lt; 100mg / dL ) and high risk ( LDLc &lt; 70 mg / dL ) .</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded after the signing of the Informed Consent ( IC) and until the end of the study.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">632</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Valsartan 160mg + Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 320mg + Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diovan® 160mg + Crestor® 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diovan® 320mg + Crestor® 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg + Rosuvastatin 20mg</intervention_name>
    <description>1 tablet, oral, a day</description>
    <arm_group_label>Valsartan 160mg + Rosuvastatin 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 320mg + Rosuvastatin 20mg</intervention_name>
    <description>1 tablet, oral, a day</description>
    <arm_group_label>Valsartan 320mg + Rosuvastatin 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diovan® 160mg + Crestor® 20mg</intervention_name>
    <description>Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.</description>
    <arm_group_label>Diovan® 160mg + Crestor® 20mg</arm_group_label>
    <other_name>Valsartan 160mg + Rosuvastatin 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diovan® 320mg + Crestor® 20mg</intervention_name>
    <description>Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.</description>
    <arm_group_label>Diovan® 320mg + Crestor® 20mg</arm_group_label>
    <other_name>Valsartan 320mg + Rosuvastatin 20mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of both sexes aged between 18 and 65 years;

          -  Participants diagnosed with uncontrolled hypertension;

          -  Participants with intermediate and high risk dyslipidemia, according to the V
             Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;

          -  Ability to understand and consent to participate in this clinical study, manifested by
             signing the Informed Consent and Informed ( IC) .

        Exclusion Criteria:

          -  Participants with a previous diagnosis of familial hypercholesterolemia (homozygous);

          -  Concomitant use of angiotensin II receptor blocker (ARB) or inhibitor of angiotensin
             converting enzyme (ACE);

          -  participants with isolated hypertriglyceridemia (TG ≥150 mg / dL) according to V
             Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;

          -  research participants with total cholesterol (TC) above 500 mg / dL or triglyceride
             (TG) above 400 mg / dL;

          -  participants with systolic blood pressure ≥180 mmHg or diastolic ≥110 mmHg;

          -  research participants with postural hypotension (SBP decrease ≥20 mmHg or DBP ≥10 mmHg
             in orthostatic position in relation to the sitting position);

          -  History of congestive heart failure (CHF) functional class III or IV (NYHA);;

          -  any clinical, laboratory and electrocardiographic that, in the judgment of the
             investigator, may interfere with the safety of research participants;

          -  Creatine phosphokinase (CPK) levels above the established laboratory normal range;

          -  Transaminases (ALT and ASL) serum above 2 times the established laboratory normal
             range;

          -  Body mass index (BMI) ≥35 kg / m²;

          -  Immunocompromised participants (eg .: malignancies, patients with Acquired
             Immunodeficiency Syndrome etc);

          -  Chronic use of drugs that may interact with the drugs of the study;

          -  Patients on concomitant lipid-lowering therapy;

          -  History hypersensitivity to the active ingredients used in the study;

          -  Participants who are pregnant, nursing or planning to become pregnant, or female
             participants of childbearing potential who are not using a reliable method of
             contraception;

          -  History of alcohol abuse or illicit drug use;

          -  Adherence to uniformization medication &lt;80%;

          -  Participating in the research that has participated in clinical trial protocols in the
             last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J),
             unless the investigator considers that there may be direct benefit to it;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberto B. Amazonas, M.D.</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

